BioNTech published its Sustainability Report 2024 detailing significant advancements in its clinical portfolio, the expansion of its AI research for personalized cancer treatment, and the establishment of its Global Health Office (GHO). The report emphasizes collaborations with global health organizations such as the WHO, African Union, and CEPI to improve access to innovative medicines in low- and middle-income countries, reinforcing its commitment to corporate responsibility and sustainable development.

OpenSecrets has published a profile detailing BioNTech SE's lobbying activities. The profile aggregates data on the company's efforts to influence policy through lobbying, raising concerns about corporate involvement in shaping political outcomes.

A German PR industry body, Deutschen Rates für Public Relations (DRPR), issued a warning over reports that BioNTech (along with Twitter) discussed restricting posts from vaccine equity activists. Critics say this move is intended to suppress dissent regarding vaccine distribution and technology sharing during the COVID-19 pandemic.

Emails reveal that BioNTech SE, in coordination with the German government, allegedly asked Twitter to shield the company from criticism over its refusal to share vaccine technology with low and middle-income countries. Critics argue that this move aimed to suppress legitimate discourse during the pandemic.

BioNTech released its 2023 Human Rights Policy Statement, outlining its commitment to upholding international human rights standards, including fair labor practices, diversity, environmental responsibility, and comprehensive due diligence processes across its operations and supply chain. The policy emphasizes proactive risk analysis, the implementation of training and audits, and clear grievance mechanisms.

Amnesty International's report criticized BioNTech along with other major vaccine developers for intentionally blocking technology transfer, hoarding vaccine doses, and failing to allocate vaccines equitably to low-income countries, thereby exacerbating a global human rights crisis during the Covid-19 pandemic.

Amnesty International's September 2021 report alleges that BioNTech, along with other major pharmaceutical companies, has failed to uphold its human rights obligations by refusing to share intellectual property and vaccine technology, thereby contributing to global vaccine inequality and a human rights crisis.

On May 21, 2021, BioNTech SE released its first Sustainability Report, detailing its commitment to ethical corporate practices, compliance with UN Global Compact principles, environmental responsibility including a clear pathway to climate neutrality, and robust diversity initiatives. The report also highlighted the company's 'Prime' ESG rating by ISS ESG, positioning it within the top 10% of its industry.